Serial Success With Triumvira's Rob Williamson

We love to hear from our listeners. Send us a message.

Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson isn't passive about honing his vision for progressive therapeutic dealmaking. He's an active leader, and for this episode of the Business of Biotech, he took a breather from a hectic agenda at the J.P. Morgan Healthcare Conference to share some introspection on the work he's done, the work he's doing at Triumvira with T-cell therapeutics in oncology, the big opportunities in cancer therapeutics, and what's coming next.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/